Yvonne Greenstreet, Alnylam CEO (Photo courtesy Alnylam)
March 21, 2025 02:50 PM EDT
Pharma
FDA+

Al­ny­lam hopes its broad AT­TR-CM la­bel can give Amvut­tra an edge in heart dis­ease

Max Gelman

Senior Editor

Al­ny­lam will like­ly face chal­lenges in turn­ing a prof­it this year, de­spite ex­ec­u­tives promis­ing to do so. But the la­bel for its new­ly-ap­proved Amvut­tra in­di­ca­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump think tank res­ur­rects in­ter­na­tion­al drug pric­ing mod­el to go af­ter 'glob­al free­load­ing'

Gen­fit's up to €185M roy­al­ty deal; J&J’s Trem­fya gets a Crohn's ap­proval

As­traZeneca broad­ens pres­ence in Chi­na, promis­ing $8B+ to Har­bour and Syneron

BAR­DA can­cels an­nu­al bio­med­ical event for in­dus­try, gov­ern­ment reps

The buildup to Chimerix's $935M ex­it to Jazz, with more than half a dozen par­ties in­trigued

FDA ap­proves No­var­tis’ Fab­hal­ta in an­oth­er rare kid­ney dis­ease

A service from the Financial Times